Notably, the levels of most pro-inflammatory cytokines, except for IL-6, were further reduced in the T2DM + MSC-sEVs group (P < 0.05), which suggests that the MSC-sEVs treatment has a significant inhibitory effect on specific cytokines. This evidence concerns the gene IL6 and type 2 diabetes mellitus.